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Abstract
Lysozymes are key effectors of the animal innate immunity system that kill bacteria by hydrolyzing peptidoglycan, their
major cell wall constituent. Recently, specific inhibitors of the three major lysozyme families occuring in the animal kingdom
(c-, g- and i-type) have been discovered in Gram-negative bacteria, and it has been proposed that these may help bacteria
to evade lysozyme mediated lysis during interaction with an animal host. Escherichia coli produces two inhibitors that are
specific for c-type lysozyme (Ivy, Inhibitor of vertebrate lysozyme; MliC, membrane bound lysozyme inhibitor of c-type
lysozyme), and one specific for g-type lysozyme (PliG, periplasmic lysozyme inhibitor of g-type lysozyme). Here, we
investigated the role of these lysozyme inhibitors in virulence of Avian Pathogenic E. coli (APEC) using a serum resistance
test and a subcutaneous chicken infection model. Knock-out of mliC caused a strong reduction in serum resistance and in in
vivo virulence that could be fully restored by genetic complementation, whereas ivy and pliG could be knocked out without
effect on serum resistance and virulence. This is the first in vivo evidence for the involvement of lysozyme inhibitors in
bacterial virulence. Remarkably, the virulence of a ivy mliC double knock-out strain was restored to almost wild-type level,
and this strain also had a substantial residual periplasmic lysozyme inhibitory activity that was higher than that of the single
knock-out strains. This suggests the existence of an additional periplasmic lysozyme inhibitor in this strain, and indicates a
regulatory interaction in the expression of the different inhibitors.
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Introduction
Lysozymes are key effectors of innate immunity in all animals
(for review, see 2). They catalyze the hydrolysis of b-(1–4)
glycosidic bonds between the N-acetylmuramic acid and N-
acetylglucosamine repeating units composing the backbone of
peptidoglycan, the major constituent of bacterial cell walls.
Lysozyme is a component of both phagocytic and secretory
granules of neutrophils and is also produced by monocytes,
macrophages and epithelial cells. It is found in significant
concentrations in saliva, airway mucus, milk and other secretions,
and is considered to be an important first line barrier against
bacterial infection. While many gram-positive bacteria are rapidly
killed by lysozyme in vitro, gram-negative bacteria are not because
they have an outer membrane that prevents direct access of
lysozyme to the peptidoglycan sacculus. However, in vivo, gram-
negative bacteria are sensitized to lysozyme by accessory
antimicrobial peptides of the innate immunity system such as
defensins and complement which disrupt the outer membrane
barrier [1]. Several structurally different lysozymes have been
described and the major types within the animal kingdom are the
c-type (chicken or conventional type), the g-type (goose type) and
the i-type (invertebrate type) lysozymes. Vertebrates have genes for
both c- and g-type lysozyme, but their spatio-temporal expression
is species-specific. The chicken genome for instance comprises a
single c-type and two g-type lysozyme genes. The c-type gene is
highly expressed in the oviduct under control of steroid hormones,
as well as in macrophages, where expression is further enhanced
by bacterial lipopolysaccharides [2]. In the intestine of young
chickens, c-type lysozyme gene expression was observed up to an
age of 8 days, while the g-type lysozyme genes, g1 and g2, were
expressed at all ages up to at least 38 days [3]. Further, g-type
lysozyme was identified in the liver, kidney, bone marrow and lung
tissue of chicken [3,4].
In view of the widespread occurrence of lysozymes, it is not
surprising that commensal and pathogenic bacteria colonizing
animal hosts or causing chronic infections have developed specific
lysozyme evasion mechanisms. The most recently discovered
mechanism is the production of specific lysozyme inhibitor
proteins in gram-negative bacteria. The first such inhibitor (Ivy,
inhibitor of vertebrate lysozyme) was discovered fortuitously as a
periplasmic Escherichia coli protein binding to and inhibiting with
high affinity and specificity c-type lysozymes [5]. Since then,
specific screens have resulted in the discovery of structurally
different c-type lysozyme inhibitors as well as inhibitors that are
specific for i- and g-type lysozymes [6–8], all from gram-negative
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bacteria. The newly discovered c-type inhibitor family comprises
both periplasmic members (PliC, periplasmic lysozyme inhibitor of
c-type lysozyme), and members that are bound to the luminal side
of the outer membrane (MliC, membrane bound lysozyme
inhibitor of c-type lysozyme), while the i- and g-type inhibitors
appear to be invariably periplasmic (PliI and PliG respectively).
The number of inhibitor types (or gene homologs thereof) found in
bacteria varies from none to all four. E. coli, which is the subject of
the current work, produces active Ivy, MliC and PliG. By
constructing knock-out mutants in various bacteria, all known
inhibitors were shown to be at least partially protective against
challenge with the corresponding type of lysozyme, and lysozyme
inhibitors have therefore been proposed to play a role in host
colonization by commensal or pathogenic bacteria [6–10]. In
support of this hypothesis, Ivy was shown to be essential for the
ability of E. coli to grow in human saliva and to enhance its ability
to survive in egg white of chicken eggs, both of which contain only
c-type lysozyme [10]. PliG, on the other hand, enhanced survival
of E. coli in goose egg white, which contains only g-type lysozyme,
but not in chicken egg white [11]. These results indicate that a
highly specific one-to-one interaction between host lysozymes and
bacterial lysozyme inhibitors may affect bacteria-host interactions.
However, in vivo studies which demonstrate that lysozyme
inhibitors affect the virulence of bacterial pathogens are still
lacking to date. Therefore, the objective of this work was to
investigate the role of lysozyme inhibitors in the virulence of Avian
Pathogenic E. coli (APEC) in the chicken. APEC are a subset of
extraintestinal pathogenic E. coli (ExPEC), besides uropathogenic
E. coli (UPEC) and E. coli causing neonatal meningitis and
septicemia (NMEC). In poultry, APEC are associated with
extraintestinal infections, resulting in different diseases, of which
colibacillosis, cellulitis and swollen head syndrome are the most
predominant. Therefore, APEC is the cause of one of the most
significant and widespread infectious diseases occurring in poultry
and a cause of increased mortality and decreased economic
productivity [12,13]. A number of virulence factors of APEC have
been established, including iron uptake systems [14], lipopolysac-
charide O antigens and K1 capsule [15], fimbrial adhesins [16],
autotransporter proteins [17] and a type VI secretion system [18],
but the detailed mechanisms underlying pathogenicity are still
poorly understood [19]. At the start of this study, all E. coli strains
from which a genome sequence is available at NCBI (National
Center for Biotechnology Information, http://www.ncbi.nlm.nih.
gov), including APEC O1, contained a putative ivy, mliC and pliG
gene. As such, APEC possesses the full complement of known
inhibitors that can potentially interact with the c- and g-type
lysozymes produced by the chicken. This match makes the APEC-
chicken model well suited for the purpose of this work.
Materials and Methods
Bacterial strains and media
The bacteria and plasmids used in this work are described in
Table 1. All the strains were grown in Luria-Bertani (LB) broth at
37uC. Antibiotics (Sigma-Aldrich, Bornem, Belgium) were added
when appropriate at the following final concentrations: ampicillin
(Ap), 100 mg/ml; kanamycin (Km), 50 mg/l; chloramphenicol
(Cm), 20 mg/ml.
Construction of the APEC lysozyme inhibitor deletion
and complemented strains
The deletion of ivy, mliC, pliG in APEC CH2 was achieved using
the lambda red recombinase system described by Datsenko and
Wanner [20] as adapted by Derbise et al. [21].
A three-step PCR procedure (Figure 1) was used to produce an
antibiotic resistance cassette flanked by long fragments homolo-
gous to the regions upstream and downstream of the gene to be
replaced (ivy, mliC or pliG). In a first step the antibiotic resistance
cassette from the plasmids pKD3 or pKD4 was amplified with
Phusion DNA-polymerase (Finnzymes, Espoo, Finland) using
70 bp PCR primers comprising a 50 bp 59 tail complementary
to the region directly up- (primer 1) or downstream (primer 2) of
the E. coli gene of interest. In a second step the APEC CH2
genomic DNA was used as a template in two separate PCR’s to
amplify 6200 bp fragments up- (primer 3) and downstream
(primer 4) of the inhibitor gene. To this end, the PCR product
obtained in the first step was used as a primer in combination with
a new primer either 200 bases upstream or downstream of the
gene. Finally, the products of the two PCR reactions from step 2
were combined in a third PCR step (without additional primers) to
generate a PCR product comprising the antibiotic resistance
cassette flanked by 6200 bp fragments corresponding to the
upstream and downstream regions of the inhibitor gene. Gene
disruption was carried out by electrotransformation of this final
PCR product into APEC CH2 carrying the plasmid pKD46. Km
or Cm resistant transformant colonies (depending on whether the
Km resistance cassette from pKD4 or the Cm resistance cassette
from pKD3 was used in the three-step PCR) were analysed by
PCR (using primer 4 and a control primer) and DNA sequencing
to confirm correct gene replacement. All the primers used in this
procedure for each of the inhibitor genes are listed in Table S1.
DNA sequencing was done by the Sanger method by the Division
of Gene Technology, KU Leuven.
The resulting strains were designated APEC CH2 Divy::Km,
APEC CH2 DmliC::Cm and APEC CH2 DpliG::Cm.
The double knock-out strain APEC Divy::Km DmliC::Cm was
constructed by introducing the suicide plasmid pSD19 containing
a Divy::Km allele into APEC CH2 DmliC::Cm and selecting Km-
resistant transformants. This Divy::Km allele was obtained by PCR
from E. coli TE2680, an earlier constructed ivy knock-out strain [9]
with primers 59-GATCTCTAGACGCCAGGCTTTAGGAGG-
39 and 59-GATCAAGCTTCGGAGCCGAAAGGCTCC-39, and
the resulting blunt-end PCR product was ligated into pSD19 [22]
cleaved with BamHI. Correct gene replacement was verified by
PCR and sequencing as described above.
For genetic complementation, all the inhibitor genes were
cloned in the plasmid pACYC177. The APEC CH2 pliG gene with
its own promotor was amplified with the following primers: 59-
GTGTAAGCTTGACATATAAATAGGTCTG-39 and 59-AT-
TAATCGATTTACTTAATTTGAATATC-39. After digestion
with HindIII and ClaI (recognition sites in primers are underlined),
the resulting fragment was ligated into pACYC177 opened with
the same restriction enzymes, and transformed into APEC CH2
DpliG::Cm. In a similar way, the APEC CH2 mliC gene and its
promoter were amplified using the primers: 59-ATTAATCGA-
TACCCGTATTTCTCGCAA-39 and 59-TAGCGC-
TAGCCTTTACGGATTGTCAGTG-39. After digestion with
ClaI and NheI, the resulting fragment was ligated into pACYC177
cleaved with the same enzymes, and transformed into APEC CH2
DmliC::Cm. The two resulting plasmids were designated as
pACYC-pliG and pACYC-mliC. Finally, the APEC CH2 ivy gene
amplified with the primers 59-ATATGGTACCGCCGCTGG-
TAAACATCTC-39 and 59-GAT-
CAAGCTTGCGCTCCGTTTCTTTATCC-39 was ligated into
pACYC177 and pACYC-mliC opened with SmaI. The resulting
plasmids pACYC-ivy and pACYC-ivy/mliC were respectively
transformed into APEC CH2 Divy::Km and APEC CH2 Divy::Km
DmliC::Cm.
Bacterial Lysozyme Inhibitor Involved in Virulence
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e45954
Isolation of periplasmic proteins
Periplasmic proteins were isolated by a cold osmotic shock
procedure. In short, cells grown with shaking for 21 h in 50 ml LB
broth at 37uC, harvested by centrifugation (10 min, 2900 g, room
temperature), and resuspended in 6.25 ml 30 mM Tris-HCl
(pH 8.0) with 20% (w/v) sucrose. After addition of 0.625 ml
10 mM EDTA (pH 8.0) and shaking for 10 min at room
temperature, the sample was centrifuged (10 min, 6350 g, 4uC)
and the cell pellet resuspended and shaken for 10 min in 6.25 ml
ice-cold 5 mM MgSO4. This suspension was centrifuged again
(10 min at 16800 g, 4uC), and the supernatant, corresponding to
the periplasmic fraction, was stored at 220uC until further
analysis.
Lysozyme inhibition assay
Lysozyme inhibitory activity of bacterial periplasmic extracts
was measured as described by Callewaert et al. [6] for c-type and
by Vanderkelen et al. [8] for g-type lysozyme inhibitors, using
respectively hen egg white lysozyme (HEWL; Fluka, 66000 U/mg
protein) and recombinantly expressed g-type lysozyme from
Atlantic salmon (SalG) [23].
Serum resistance
For the serum resistance assay, all strains were grown 24 h in
LB at 37uC. Blood was collected from healthy adult chickens and
pooled. After clotting, normal chicken serum was isolated by
centrifugation for 15 min at 3000 rpm. Inactivated chicken serum
was prepared by incubating normal chicken serum in a waterbath
at 56uC for 25 min to inactivate the complement system.
Subsequently, the APEC strains and the serum-sensitive strain E.
coli BL21 as a negative control were inoculated in the chicken
serum at a concentration of approximately 105 CFU/ml. Bacterial
counts were determined immediately and after 3 h of incubation
at 37uC by plating appropriate dilutions on LB plates.
In vivo virulence test
Bacteria cultured for two subsequent periods of 24 h in LB at
37uC were diluted 1/100 in 4 ml fresh LB medium without
antibiotics and grown until late exponential phase
(OD600 nm= 0.6, approximately 5610
8 CFU/ml). Part of this
culture was diluted in LB to 56107 CFU/ml and 56106 CFU/ml.
Colony counts were determined for each dilution by plating on LB
agar to confirm these titers. Two hundred mL of each dilution was
injected subcutaneously in the necks of 10 1-day-old broiler chicks
(Ross Line, Belgabroed NV, Merksplas, Belgium), and mortality
was monitored for 7 days. Control groups received 200 mL of
sterile LB medium or 56108 CFU/ml of the non-pathogenic
strain E. coli BL21. All experiments on animals were approved by
the Ethical Commission for Experimental Use of Animals of the
Katholieke Universiteit Leuven (Project number P116/2008).
Statistical analysis
The statistical analyses of the in vivo experiments were
performed using SAS software, version 8.2 (SAS Institute, Cary,
NC, USA). Mortality rates for different strains with the same
dosage were compared using the Kruskal-Wallis test.
Results
Construction of APEC CH2 inhibitor knock-out mutants
Since no genome sequence of APEC CH2 was available, we first
confirmed by PCR and sequencing the presence of lysozyme
inhibitor genes known to occur in other E. coli strains (ivy, mliC and
pliG) in this strain (data not shown). To investigate the role of these
lysozyme inhibitors in APEC virulence, we then constructed
knock-outs of each of the genes, as well as a double ivy and mliC
knock-out in order to have a strain producing neither c-type
inhibitor. Each knock-out strain was also genetically complement-
ed with a plasmid-borne copy of the corresponding gene(s), and
the wild-type strain APEC CH2 was equipped with an empty
Table 1. Strains and plasmids.
Strain Properties Source
E. coli BL21 Novagen, Merck Biosciences, Darmstadt,
Germany
APEC CH2 APEC strain CH2 is a virulent O78 papGII+ strain [31,32]
APEC CH2 Divy::Km ivy gene replaced by aph gene from pKD4; KmR This study
APEC CH2 DmliC::Cm mliC gene replaced by cat gene from pKD3; CmR This study
APEC CH2 Divy::Km DmliC::Cm APEC CH2 DmliC::Cm with Divy::Km allele from E. coli TE2680; KmR, CmR This study, [9]
APEC CH2 DpliG::Cm pliG gene replaced by cat gene from pKD3; CmR This study
Plasmid Properties Source
pKD3 Vector containing cat gene flanked by FRT sites, CmR [20]
pKD4 Vector containing aph gene flanked by FRT sites, KmR [20]
pKD46 Plasmid expressing c, b and exo recombination genes of phage l under
control of PBAD; temperature-sensitive replicon, Ap
R
[20]
pSD19-Divy::Km Divy::Km in pSD19, oriP1, CmR This study
pACYC177 ApR; New England Biolabs, Inc., Beverly, MA
pACYC-ivy ivy under control of its own promotor in pACYC177; ApR This study
pACYC-mliC mliC under control of its own promotor in pACYC177 CmR, ApR This study
pACYC-ivy/mliC ivy and mliC under control of their own promotor in pACYC177, ApR This study
pACYC-pliG pliG under control of its own promotor in pACYC177 CmR, ApR This study
doi:10.1371/journal.pone.0045954.t001
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pACYC177 plasmid to detect any potential influence of the
presence of the plasmid. The successful construction of the
inhibitor knock-out mutants as well as the plasmids was confirmed
by PCR and sequencing. Subsequently, periplasmic extracts of all
the strains were analyzed for inhibitory activity against c- and g-
type lysozyme (Table 2). Since MliC is an outer membrane
protein, we also attempted to measure the loss of inhibitory activity
in the membrane fraction of the mliC mutant, but no activity
exceeding the noise level could be detected even in the wild-type
strain. This was not unexpected, because we had observed
previously that also E. coli MG1655 does not produce detectable
MliC levels, and because mliC is poorly expressed under normal
laboratory growth conditions [6]. All knock-outs caused a
considerable reduction of the periplasmic lysozyme inhibitory
activity, but the residual activities varied. Knock-out of pliG
reduced g-type inhibitory activity in the periplasmic extract to a
background level, while the c-type inhibitory activity was only
partly reduced in the ivy knock-out. The latter was unexpected,
because Ivy is the only known periplasmic lysozyme inhibitor in E.
coli, and knock-out of ivy completely eliminated c-type lysozyme
inhibitory activity in periplasmic extracts of E. coli MG1655 [9].
Finally, double knock-out of ivy and mliC also reduced c-type
inhibitory activity in the periplasmic extracts, but somewhat less
than the individual ivy knock-out. Complementation of each
knock-out strain with the corresponding gene or genes increased
the inhibitory activity back to the wild-type level. All the
constructed knock-out mutants and genetically complemented
mutants showed growth curves in LB broth at 37uC that were
undistinguishable from the parental APEC CH2 growth curve
(data not shown).
Serum sensitivity
As a first approach to assess the virulence of the different APEC
inhibitor knock-outs, a serum sensitivity test was conducted. For
many pathogens including APEC, the ability of bacteria to survive
and grow in blood serum is a prerequisite for virulence and has
proven useful in discriminating virulent and avirulent isolates [24].
Serum resistance depends on the ability of the bacteria to
overcome the combined antibacterial effectors that are present
in serum. One of the most powerful effectors is the multimolecular
Figure 1. Scheme of three-step PCR to prepare DNA fragments for chromosomal gene replacement. In a first step, an antibiotic
resistance cassette is amplified using primers carrying 59 end 50 bp extensions homologous to the upstream (primer 2) and downstream (primer 1)
region of the target inhibitor gene in APEC. The resulting PCR product is then used in a second step in combination with two other primers (primer 3
and primer 4) to separately amplify a larger part of the downstream and the upstream regions of the target gene. This results in two products which
consist of the resistance marker cassette flanked by an upstream or a downstream 200 bp (or more) region homologous to the target gene. In a third
step these two products are combined and amplified, resulting in a fusion product that has a large upstream and downstream homology region at
either side of the resistance marker, and that is used for gene replacement.
doi:10.1371/journal.pone.0045954.g001
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attack complex formed by the complement system [25], but there
is also a contribution of several antibacterial peptides and proteins
with specific modes of action, such as lysozyme. The results of the
serum resistance tests are shown in Table 3. All strains including E.
coli BL21, which was included as a serum-sensitive control, showed
strong growth in serum that had been heat-treated to inactivate
the complement system (plate counts increasing 250- to 350-fold
after 3 h, no significant differences). In untreated serum, growth of
BL21 and APEC CH2 was reduced to 13.8% and 60.2% of the
growth level in heat-treated serum, respectively, indicating that the
avirulent and virulent controls could be distinguished in the serum
test (p,0.05). For three APEC mutants, the reduction in growth in
untreated serum was in the same range as for the parent strain
(60–70%), but for the mliC mutant, a reduction to the level of
BL21 was observed (10.3%). This result implicates that the mliC
knock-out strain could have a reduced virulence whereas the ivy
mliC knock-out strain and the other inhibitor knock-out strains are
considered to be as virulent as the wild-type APEC strain. To
confirm these observations, the virulence of the strains was
analyzed in vivo.
In vivo virulence
A first in vivo experiment was conducted with the ivy, mliC and ivy
mliC mutants to investigate the role of the c-type lysozyme
inhibitors in virulence. The mortality curves up to 7 days post
infection are shown in Figure 2. The laboratory strain E. coli BL21,
included as a negative control, was confirmed to be non-virulent
since no chicks died even with the highest dose of 108 CFU per
animal (data not shown). On the other hand, the wild-type CH2
strain caused a dose-dependent mortality, and even at the lowest
dose of 106 CFU/animal killed 6 out of 10 chicks after 7 days.
Interestingly, virulence was clearly reduced by knock-out of MliC
as anticipated by the outcome of the serum resistance test. At a
dose of 108 CFU/animal the onset of mortality for the mliC
mutant showed a statistically significant delay of one day
compared to the wild-type (p= 0.0076), and this mutant killed
less animals after 7 days compared to the wild-type strain and the
complemented mliC mutant, although this difference was not
significant. However, at lower doses the reduced mortality with the
mliC mutant became more pronounced. At 107 CFU/animal, the
difference with the wild-type strain was significant from day 1 to
day 4, while at 106 CFU/animal it was significant from day 4 until
the end of the observation period (Figure 2). At this dose, the
chicks infected with the mliC mutant showed 100% survival
compared to only 50% for the wild-type strain (p = 0.0118).
Complementation of the knock-out with a plasmid-borne mliC
gene reverted the mortality rate to wild-type level (50%). With
respect to complementation, the control experiment with the wild-
type strain containing the empty cloning vector pACYC177
indicated the absence of any significant effect of the plasmid on the
mortality rates. A more quantitative analysis was performed by
calculating LD50 values from the data of this experiment according
to the method of Reed and Muench [26], and this revealed an at
least thirtyfold increased LD50 for the mliC knock-out strain
(3.26107 CFU/chick) compared to the wild-type (1.06106 CFU/
chick). This in vivo experiment was repeated, resulting in similar
mortality curves (Figure S1) and identical LD50 values. As opposed
to mliC, ivy had no major detectable effect on virulence in both
infection experiments. However, similar as in the serum test, the
ivy mliC double knock-out caused higher mortalities than the mliC
mutant at a dose of 107 CFU/ml (p = 0.0014) and at a dose of
106 CFU/ml (p= 0.0671). At the lowest infection dose of
106 CFU/ml the mortality caused by mliC differs significantly
from the mortality caused by all the other strains (p,0.05) except
for the double knock-out strain (p = 0.0671).
A separate challenge experiment was conducted with the pliG
knock-out strain, its complemented derivative and the wild-type
Table 2. Inhibitory activity of periplasmic extracts of different APEC strains.
Strain Inhibitory activitya (IU/ml) against HEWL Inhibitory activity* (IU/ml) against SalG
APEC CH2 34.262.7 18.162.0
APEC CH2 Divy::Km 8.361.7a nd
APEC CH2 Divy::Km pACYC-ivy 34.762.3 nd
APEC CH2 DmliC::Cm 8.063.6a nd
APEC CH2 DmliC::Cm pACYC-mliC 18.5610.0 nd
APEC CH2 Divy::Km DmliC::Cm 14.661.5a nd
APEC CH2 Divy::Km DmliC::Cm pACYC-ivy/mliC 34.861.8 nd
APEC CH2 DpliG::Cm nd 2.560.5a
APEC CH2 DpliG::Cm pACYC-pliG nd 23.466.3
*Experiments were performed in triplicate and mean inhibitory activity (IU/ml) and standard deviation are shown. Since MliC is a membrane protein, its activity can not be
measured in a periplasmic extract.
aInhibitory activity differing significantly (p,0.05) from that of the wild-type strain in the same column.
doi:10.1371/journal.pone.0045954.t002
Table 3. Serum resistance of different APEC strains.
Strain Relative growtha in serum
E. coli BL21 13.869.5%*
APEC CH2 60.262.1%
APEC CH2 Divy::Km 60.264.3%
APEC CH2 DmliC::Cm 10.362.9%*
APEC CH2 Divy::Km DmliC::Cm 64.566.0%
APEC CH2 DpliG::Cm 71.6629.1%
aRelative growth is the increase in plate count (N3 h/N0 h) in serum expressed
relative to the increase in plate count in heat-inactivated serum ( = 100%). N3 h/
N0 h ranged between 240 and 347 in heat-inactivated serum. Mean
values+standard deviations for three independent cultures are shown. Significant
differences (p,0.05) with the wildtype APEC CH2 strain are indicated with an
asterisk.
doi:10.1371/journal.pone.0045954.t003
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strain, but no significant differences in mortality rates were
observed at any of the three applied doses (Figure 2).
Discussion
In this work we investigated the role of lysozyme inhibitors in
bacterial virulence using an APEC – chicken model system. Single
knock-outs of ivy, mliC and pliG as well as an ivy/mliC double
knock-out were successfully constructed in APEC CH2, and
plasmid-based complementation of the mutants with the corre-
sponding genes was accomplished. First we determined the serum
resistance of the mutants as a rapid and simple indicator of
virulence, and found that mliC, but not ivy or pliG, was required for
serum resistance of APEC CH2. Although bacterial sensitivity to
serum is mainly due to the action of the complement system, there
is also a contribution of other antimicrobial components such as
lysozyme. The action of the membrane attack complex of the
complement system destabilizes the outer membrane and may
render it permeable to lysozyme. Conversely, degradation of the
peptidoglycan layer may facilitate pore formation in the cytoplas-
mic membrane by the membrane attack complex, resulting in cell
leakage an death [27]. Our results suggest that MliC can
neutralize this contribution of serum lysozyme to complement
activity. Given the effect of the single knock-outs, the parental level
of serum resistance in the mliC ivy double knock-out was
unexpected (see also below).
Subsequently, infection experiments with 1-day old chickens
subcutaneously injected with different doses of bacteria (106, 107
and 108 CFU/chick) confirmed the attenuated virulence of the
mliC mutant. In addition, virulence was fully restored by
complementation with the mliC gene. As anticipated from the
serum resistance test, pliG nor ivy had any significant effect on
virulence. Since PliG is the only known inhibitor of g-type
lysozyme in APEC, and its knock-out reduced g-type lysozyme
inhibitory activity of APEC CH2 to background levels, it can be
concluded that PliG is not required for virulence of this pathogen,
at least not in the subcutaneous infection model used in this work.
Of course, a role of this inhibitor in other commensal or
pathogenic bacteria – host interactions can not be excluded on
the basis of these observations. For the c-type lysozyme inhibitors,
the situation is more complex. Based on the observations with the
single knock-out strains, the outer membrane-bound inhibitor
MliC appears to play a role in virulence, but not the periplasmic
inhibitor Ivy. Since MliC is an outer membrane protein, there
could be some concern that knock-out of MliC could have
destabilized the outer membrane, thus rendering the bacteria
more sensitive to a variety of antibacterial effectors from its host.
This appears not to be the case, because the mliC mutant retained
its resistance to detergents when plated on LB containing 2.0%
SDS or 2.0% Triton X-100 (data not shown), whereas mutants
with outer membrane defects typically display a high serum and
detergent sensitivity [28,29]. Therefore, we can have confidence
that the attenuated virulence of the mliCmutant is genuinely linked
Figure 2. Mortality curves of 1-day old chickens upon subcutaneous infection with APEC strains. Number of surviving animals up to 7
days post infection with APEC CH2 (N), APEC CH2 pACYC177 (empty plasmid control) (#), APEC inhibitor knock-out (&) and the corresponding
complemented APEC inhibitor knock-out strain (%). Time points where the number of survivors with the inhibitor knock-out was significantly
different from that with the wild-type are marked with ‘*’ and the corresponding p-value.
doi:10.1371/journal.pone.0045954.g002
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to its reduced production of c-type lysozyme inhibitor rather than
to an indirect effect. One point that needs further clarification is
which inhibitor is responsible for the attenuated virulence, since
the mliCmutant unexpectedly showed a considerably reduced level
of periplasmic lysozyme inhibitor activity (Table 2).
An additional complication, in line with the observations in the
serum resistance test, is that introduction of an ivy knock-out into
the mliC mutant restored the attenuated virulence of the latter to
almost wild-type level again, indicating that there is some type of
interference between these two mutations. Comparison of the
periplasmic lysozyme inhibitory activities confirms that this is
indeed the case, because the level in the double mutant (14.6 IU/
ml) is higher than that in the mliC mutant (8.0 IU/ml). For
comparison, an ivy mliC mutant of E. coli MG1655 was previously
shown to have no residual periplasmic lysozyme inhibitory activity
[6], but an explanation for this strain-dependent behaviour is
currently lacking. However, we found that two E. coli genome
sequences that were added to the NCBI genome database during
the preparation of our manuscript contain a pliC homolog in
addition to ivy and mliC, unlike all other E. coli genomes. This is not
the case for the APEC O1 genome, but nevertheless, the residual
periplasmic lysozyme inhibitory activity of the APEC CH2 ivy
knock-out could indicate that this strain also has an additional pliC.
In conclusion, this work is the first to demonstrate the
involvement of a lysozyme inhibitor in bacterial virulence.
Although findings from the APEC – chicken model system studied
in this work cannot be simply extrapolated to other pathogen –
host interactions, the wide distribution of different types of
lysozyme inhibitors in bacteria suggests that these molecules have
evolved as virulence factors or effectors of commensal interactions
in a wide range of bacteria. This finding may also open
perspectives for new avenues for the development of antibacterial
drugs, for example by designing compounds that can neutralize
bacterial lysozyme inhibitors, thus rendering them more sensitive
to the host lysozymes [30].
Supporting Information
Figure S1 Mortality curves of 1-day old chickens upon
subcutaneous infection with APEC strains (repeat experiment).
Number of surviving animals up to 7 days post infection with
APEC CH2 (N), APEC CH2 pACYC177 (empty plasmid control)
(#), APEC inhibitor knock-out (&) and the corresponding
complemented APEC inhibitor knock-out strain (%). Time points
where the number of survivors with the inhibitor knock-out was
significantly different from that with the wild-type are marked with
‘*’ and the corresponding p-value.
(TIF)
Table S1 Oligonucleotide primers used for construction and
verification of the APEC inhibitor knock-out mutants by three-step
PCR procedure. Primer numbering from 1 to 4 for each inhibitor
corresponds with numbering in Figure 1, which explains
construction of the gene replacement cassettes by three-step
PCR procedure.
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